Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oncolytic Herpes Simplex Virus Type 1 (oHSV-1)
- Target
- oHSV-1
- Molecular classification
- Virus, Oncolytic Virus
01
Overview
Oncolytic herpes simplex virus type 1 (oHSV-1) is a genetically engineered or naturally occurring strain of HSV-1 designed to selectively infect, replicate within, and lyse tumor cells while sparing normal tissues. This process not only directly destroys cancer cells but also stimulates antitumor immune responses. Engineered safety features ensure selective targeting while minimizing risk to healthy tissues. This dual mechanism underpins its growing role in modern cancer therapy.
- Other names
- T-VEC (Talimogene laherparepvec)Engineered HSV-1Modified HSV-1
02
Mechanism of action
Direct tumor cell lysis and induction of antitumor immune responses
03
Biological functions
Tumor cell lysisImmunogenic cell deathAntitumor immunity inductionViral replication
04
Disease associations
Cancer
05
Safety considerations
Off-target infectionImmune-related adverse eventsPotential for viral sheddingRisk of encephalitis or disseminated HSV infection (rare)
06
Interacting drugs
Talimogene laherparepvec (T-VEC)
07
Biomarkers
Tumor-associated antigensDAMPs (ATP, HMGB1, calreticulin)Viral antigens
Beyond the preview
Go deeper on Oncolytic Herpes Simplex Virus Type 1 (oHSV-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncolytic Herpes Simplex Virus Type 1 (oHSV-1).